ERBB2 and neoplasm: In order to evaluate HER1-HER2 activated forms as potential biomarkers of targeted drug response, cell lines characterized by flow cytometry and lysate assays just described were utilized to develop VeraTagTM assays that measure HER1-HER2 heterodimerization and activation in FFPE tumor tissue (Figure 3a).